Previous 10 | Next 10 |
Baudax Bio, Inc. (BXRX) Q1 2022 Earnings Conference Call May 5, 2022, 8:30 AM ET Company Participants Sam Martin - Investor Relations Gerri Henwood - President and CEO Conference Call Participants Greg Aurand - Noble Capital Presentation Operator Good morning. And welcome to the Baudax Bio Fi...
1Q 2022 revenues reported. Late Wednesday the 4th, Baudax Bio released their 1Q 2022 results and held a conference call early on the 5th. Revenues of $.422 million, somewhat due to timing differences, missed our estimate of $.577 million. Covid still muted Q1 procedures, but procedure growth s...
MALVERN, Pa., May 05, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) (the “Company”), a pharmaceutical company focused on innovative products for acute care settings, today announced that it has adjourned its 2022 Annual Meeting of Shareholders (the “Annual Mee...
Baudax Bio press release (NASDAQ:BXRX): Q1 GAAP EPS of -$3.17 misses by $1.32. Revenue of $0.42M (+110.0% Y/Y) misses by $0.16M. Shares -6% AH. “We are actively working to expand the ANJESO label in additional patient populations. To that end, we commenced a Phase IV clinical trial eva...
ANJESO ® Net Product Revenue Up 113% Compared to Same Period in Prior Year; Sixth Consecutive Quarter of Demand Growth First Cohort Dosed in Pediatric ANJESO Surgical Study Management to Host Investor Conference Call and Webcast Tomorrow at 8:30 a.m. ET ...
Baudax Bio (NASDAQ:BXRX) is scheduled to announce Q1 earnings results on Thursday, May 5th, before market open. The consensus EPS Estimate is -$1.85 (vs. -$0.27 in Q121) and the consensus Revenue Estimate is $0.58M (vs. $0.2M last year). Over the last 3 months, EPS estimates have seen 1 ...
MALVERN, Pa., May 02, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on innovative products for acute care settings, today announced that it will report first quarter 2022 financial results on Thursday, May 5, 2022. Baudax Bio will host a conferenc...
Baudax Bio (BXRX) formal corporate presentation from NobleCon18 - Noble Capital Markets 18th Annual Small & Microcap Investor Conference - April 2022. Read More >>
NobleCon 18. Gerri Henwood, President and Chief Executive Officer, presented at the conference. The presentation highlighted continued ANJESO growth, reduced cash burn and pipeline progress of the Company’s Neuromuscular Blockers (NMBs) and NMB Reversal Agents. A replay of the presentat...
MALVERN, Pa., April 13, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on commercializing and developing innovative products for acute care settings, today announced that Gerri Henwood, the Company’s President and Chief Executive Officer, wi...
News, Short Squeeze, Breakout and More Instantly...
Baudax Bio Inc. Company Name:
BXRX Stock Symbol:
NYSE Market:
Evolv Technologies Holdings Inc. (EVLV) is expected to report $-0.14 for Q4 2023 The Lion Electric Company (LEV) is expected to report $-0.1 for Q4 2023 Fisker Inc. Class A (FSR) is expected to report $-0.2 for Q4 2023 Y-mAbs Therapeutics Inc. (YMAB) is expected to report $-0.19 for Q...
Laser Photonics Corporation (LASE) is expected to report for Q2 2024 QuickLogic Corporation (QUIK) is expected to report $0.08 for Q3 2023 Stryve Foods Inc. (SNAX) is expected to report $-1.65 for Q3 2023 Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023 V...
Baudax Bio Inc. (BXRX) is expected to report $-0.53 for Q3 2023